vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $57.2M, roughly 2.0× Vanda Pharmaceuticals Inc.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs -246.8%, a 280.2% gap on every dollar of revenue. On growth, BYLINE BANCORP, INC. posted the faster year-over-year revenue change (9.0% vs 7.6%). Over the past eight quarters, Vanda Pharmaceuticals Inc.'s revenue compounded faster (9.8% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
BY vs VNDA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $57.2M |
| Net Profit | $37.6M | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | — | -70.5% |
| Net Margin | 33.4% | -246.8% |
| Revenue YoY | 9.0% | 7.6% |
| Net Profit YoY | 33.0% | -2774.3% |
| EPS (diluted) | $0.83 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $57.2M | ||
| Q3 25 | $115.7M | $56.3M | ||
| Q2 25 | $110.5M | $52.6M | ||
| Q1 25 | $103.1M | $50.0M | ||
| Q4 24 | $104.7M | $53.2M | ||
| Q3 24 | $101.8M | $47.7M | ||
| Q2 24 | $99.4M | $50.5M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $-141.2M | ||
| Q3 25 | $37.2M | $-22.6M | ||
| Q2 25 | $30.1M | $-27.2M | ||
| Q1 25 | $28.2M | $-29.5M | ||
| Q4 24 | $30.3M | $-4.9M | ||
| Q3 24 | $30.3M | $-5.3M | ||
| Q2 24 | $29.7M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | -70.5% | ||
| Q3 25 | 43.1% | -55.6% | ||
| Q2 25 | 35.2% | -73.2% | ||
| Q1 25 | 36.4% | -82.0% | ||
| Q4 24 | 38.6% | -19.3% | ||
| Q3 24 | 39.3% | -23.1% | ||
| Q2 24 | 40.4% | -20.1% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | -246.8% | ||
| Q3 25 | 32.1% | -40.1% | ||
| Q2 25 | 27.2% | -51.7% | ||
| Q1 25 | 27.4% | -58.9% | ||
| Q4 24 | 34.3% | -9.2% | ||
| Q3 24 | 29.8% | -11.2% | ||
| Q2 24 | 29.9% | -9.0% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $-2.40 | ||
| Q3 25 | $0.82 | $-0.38 | ||
| Q2 25 | $0.66 | $-0.46 | ||
| Q1 25 | $0.64 | $-0.50 | ||
| Q4 24 | $0.68 | $-0.09 | ||
| Q3 24 | $0.69 | $-0.09 | ||
| Q2 24 | $0.68 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $327.2M |
| Total Assets | $9.9B | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $84.9M | ||
| Q3 25 | $259.0M | $70.0M | ||
| Q2 25 | $218.3M | $81.0M | ||
| Q1 25 | $421.3M | $111.8M | ||
| Q4 24 | $563.1M | $102.3M | ||
| Q3 24 | $452.6M | $100.5M | ||
| Q2 24 | $730.5M | $103.0M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $327.2M | ||
| Q3 25 | $1.2B | $466.0M | ||
| Q2 25 | $1.2B | $486.3M | ||
| Q1 25 | $1.1B | $511.4M | ||
| Q4 24 | $1.1B | $538.5M | ||
| Q3 24 | $1.1B | $541.2M | ||
| Q2 24 | $1.0B | $542.5M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $488.9M | ||
| Q3 25 | $9.8B | $601.1M | ||
| Q2 25 | $9.7B | $624.7M | ||
| Q1 25 | $9.6B | $631.9M | ||
| Q4 24 | $9.5B | $656.2M | ||
| Q3 24 | $9.4B | $645.1M | ||
| Q2 24 | $9.6B | $651.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-29.5M |
| FCF MarginFCF / Revenue | — | -51.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $-29.4M | ||
| Q3 25 | $38.3M | $-31.6M | ||
| Q2 25 | $16.3M | $-15.3M | ||
| Q1 25 | $27.1M | $-33.1M | ||
| Q4 24 | $175.2M | $-1.8M | ||
| Q3 24 | $19.8M | $-14.6M | ||
| Q2 24 | $40.1M | $-6.9M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $-29.5M | ||
| Q3 25 | $38.0M | $-31.8M | ||
| Q2 25 | $15.2M | $-15.6M | ||
| Q1 25 | $25.0M | $-33.6M | ||
| Q4 24 | $171.2M | $-2.0M | ||
| Q3 24 | $19.1M | $-14.7M | ||
| Q2 24 | $39.4M | $-7.0M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | -51.6% | ||
| Q3 25 | 32.8% | -56.5% | ||
| Q2 25 | 13.7% | -29.6% | ||
| Q1 25 | 24.3% | -67.1% | ||
| Q4 24 | 163.5% | -3.8% | ||
| Q3 24 | 18.8% | -30.9% | ||
| Q2 24 | 39.7% | -13.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.2% | ||
| Q3 25 | 0.3% | 0.3% | ||
| Q2 25 | 1.0% | 0.6% | ||
| Q1 25 | 2.0% | 0.9% | ||
| Q4 24 | 3.8% | 0.4% | ||
| Q3 24 | 0.6% | 0.3% | ||
| Q2 24 | 0.7% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BY
Segment breakdown not available.
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
